Occudo Quantitative Strategies’s Aclaris Therapeutics ACRS Stock Holding History

Occudo Quantitative Strategies’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,504	Closed	-$14.2K	–	708
2023 Q4	$14.2K	Buy	+13,504	New	+$41.2K	﹤0.01%	745
2022 Q3	–	Sell	-11,799	Closed	-$165K	–	1141
2022 Q2	$165K	Buy	11,799 +33	+0.3%	+$462	0.01%	952
2022 Q1	$203K	Sell	11,766 -9,377	-44%	-$128K	0.02%	940
2021 Q4	$307K	Sell	21,143 -6,172	-23%	-$93.5K	0.03%	754
2021 Q3	$492K	Buy	27,315 +6,949	+34%	+$111K	0.06%	548
2021 Q2	$358K	Buy	20,366 +7,323	+56%	+$166K	0.05%	530
2021 Q1	$329K	Buy	+13,043	New	+$255K	0.07%	460

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Occudo Quantitative Strategies's ACRS Position: Q1 2024 in Review

Occudo Quantitative Strategies sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 13,504 shares — an estimated $14.2K sold.

Occudo Quantitative Strategies first reported a position in ACRS in Q1 2021 and held it in 7 quarters. The position peaked at $492K in Q3 2021. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

Occudo Quantitative Strategies reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
Occudo Quantitative Strategies sold 13,504 Aclaris Therapeutics shares in Q1 2024, an estimated $14.2K.
Occudo Quantitative Strategies first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 7 quarters.
Occudo Quantitative Strategies's Aclaris Therapeutics position peaked at $492K in Q3 2021.
98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2024, filed 15 May 2024.